The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's current EPS (TTM) is $2.36. In 2024 the company made an earnings per share (EPS) of $2.41 a decrease over its 2023 EPS that were of $2.75.
Year | EPS | Change |
---|---|---|
2025 (TTM) | $2.36 | -2.08% |
2024 | $2.41 | -12.39% |
2023 | $2.75 | -58.95% |
2022 | $6.69 | 2.49% |
2021 | $6.53 | 121.58% |
2020 | $2.95 | -44.7% |
2019 | $5.33 | 45.84% |
2018 | $3.66 | 9.72% |
2017 | $3.33 | -9.54% |
2016 | $3.68 | 16.28% |
2015 | $3.17 | 184.1% |
2014 | $1.11 | -57.15% |
2013 | $2.60 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | $1.39 | -41.04% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | $2.68 | 13.68% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $12.36 | 424.11% | ๐บ๐ธ USA |
![]() Amgen AMGN | $11.05 | 368.71% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | $4.78 | 102.75% | ๐บ๐ธ USA |
![]() Biogen BIIB | $10.16 | 330.96% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | $1.56 | -33.85% | ๐ฌ๐ง UK |
![]() AstraZeneca AZN | $2.50 | 6.25% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | $3.03 | 28.52% | ๐บ๐ธ USA |